Relapsed Or Refractory Mantle Cell Lymphoma clinical trials

Explore recruiting relapsed or refractory mantle cell lymphoma clinical trials.

Recruiting relapsed or refractory mantle cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Mantle Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Bcl 2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Germany, Poland, France, Spain, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Germany, France, Italy, Poland, Spain, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma

Czechia, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs)

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Relapsed Or Refractory Mantle Cell Lymphoma trials by city

Relapsed Or Refractory Mantle Cell Lymphoma in Toronto Relapsed Or Refractory Mantle Cell Lymphoma in Vancouver Relapsed Or Refractory Mantle Cell Lymphoma in Montreal Relapsed Or Refractory Mantle Cell Lymphoma in Calgary Relapsed Or Refractory Mantle Cell Lymphoma in Edmonton Relapsed Or Refractory Mantle Cell Lymphoma in Ottawa Relapsed Or Refractory Mantle Cell Lymphoma in Winnipeg Relapsed Or Refractory Mantle Cell Lymphoma in Quebec City Relapsed Or Refractory Mantle Cell Lymphoma in Hamilton Relapsed Or Refractory Mantle Cell Lymphoma in Kitchener Relapsed Or Refractory Mantle Cell Lymphoma in London Relapsed Or Refractory Mantle Cell Lymphoma in Halifax Relapsed Or Refractory Mantle Cell Lymphoma in New York Relapsed Or Refractory Mantle Cell Lymphoma in Los Angeles Relapsed Or Refractory Mantle Cell Lymphoma in Chicago Relapsed Or Refractory Mantle Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease